Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Medtronic (NYSE: MDT) received FDA clearance to expand its Hugo robotic-assisted surgery system into general surgery procedures in the United States. The expanded 510(k) clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection. It also covers lower abdominal inguinal hernia procedures and appendectomy, expanding U.S. use beyond urology.
Medtronic said global Hugo procedure growth is running at more than twice the robotic surgery market's growth, with procedure volume on track to surpass 50,000 by its fiscal year-end. Outside the United States, general surgery represents Hugo's highest procedure growth, surpassing urology and gynecology. The system is in clinical use at a growing number of U.S. hospitals and health systems.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointFDA clearance expands Hugo's U.S. use beyond urology into upper abdominal general surgery, inguinal hernia procedures and appendectomy.
- Moderate pointGlobal Hugo procedure growth is running at more than twice the robotic surgery market's growth.
- Minor point. Forward-looking: it has not happened yet and may not happen.Hugo procedure volume is on track to surpass 50,000 by Medtronic's fiscal year-end, the company said.
- Minor pointGeneral surgery outside the U.S. represents Hugo's highest procedure growth, surpassing urology and gynecology.
Negative
- None.
News Explained
The FDA clearance expands permitted U.S. Hugo use to procedures accounting for about 3.5 million surgeries annually—more than half of U.S. soft-tissue procedures.
Key Figures
- Annual U.S. procedures covered
- about 3.5 million surgeries annually
- Procedures included in the general surgery clearance
- Hugo procedure growth
- more than two times the robotic surgery market
- Global Hugo RAS procedure growth
- Procedure milestone
- on track to surpass 50,000 procedures
- Global Hugo RAS procedures by the end of the Medtronic fiscal year
Previous Fda approval Reports
-
FDA clearance added LigaSure vessel-sealing technology to Hugo's U.S. robotic-assisted surgery portfolio.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
510(k) regulatory
cholecystectomy medical
roux-en-y gastric bypass medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
An expanded
GALWAY,
The clearance covers all upper abdominal general surgical procedures, including but not limited to cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection. Additionally, lower abdominal procedures of inguinal hernia and appendectomy were cleared. Combined, these procedures account for about 3.5 million surgeries annually in the
This clearance extends the Hugo RAS system's reach into surgical specialties where Medtronic technologies in open and laparoscopic approaches have been used for more than a half century.
"For decades, Medtronic has partnered with general surgeons, and we're bringing that same commitment to robotic surgery for
The Hugo RAS system is in clinical use at a growing number of health systems and hospitals across the
For
"As an academic health system serving communities across
Medtronic brings robotics, instruments, data, and expertise together with the goal of making surgery more precise, predictable, and personalized — and more accessible to more patients around the world. Alongside the Hugo RAS system and its connected surgical ecosystem, the company's distribution of the Sentire™* surgical system in select markets outside the
Learn more at medtronic.com/HugoSpecialties.
Medtronic is the sole authorized distributor of Cornerstone Robotic's Sentire™* surgical system outside of
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777
Ingrid Goldberg
Investor Relations
+1-763-505-2696
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assisted-surgery-ras-system-302941366.html
SOURCE Medtronic plc
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.